

AAMI Consensus Report

End User Disclosures for Emergency Use

**Ventilatory Assistance
Helmet (VAH)**

AAMI/CR509:2020

End user disclosures for emergency use Ventilatory Assistance Helmet (VAH)

Revisions are expected to be made to this document as the COVID-19 situation evolves. Please go to https://www.aami.org/covid_cr to find the most current version as well as past versions. This document is freely available and may be shared with all interested stakeholders. Contact celliot@ami.org with any comments or questions.

Approved 16 July 2020 by
AAMI

Abstract: Identifies safety related disclosures to be provided to end users of Emergency Use VAH. These details are based on the hazards identified in IEC 60601-1 and ISO 17510.

Keywords: COVID-19

AAMI Consensus Report

A Consensus Report (CR) is a publication of the Association for the Advancement of Medical Instrumentation (AAMI) developed to provide concise, prompt and practical guidance on narrowly focused topics of high importance to the health technology community. A Consensus Report is intended provide initial consensus guidance in response to an urgent/immediate need for guidance in the following instances:

- While more robust data/information develops on emergent areas
- When variation in the development, implementation or use of a product or process exists
- When existing standards or other documents require additional context/clarification

A Consensus Report is not subject to the same formal process as a standard and while similar in nature to a technical information report (TIR), a CR is based on the collective knowledge and experience of a selected group of stakeholders and has not undergone the wider reviews of a TIR or standard and offers an even greater response time.

CAUTION NOTICE: This AAMI CR may be revised or withdrawn at any time. Because it addresses a rapidly evolving field or technology, readers are cautioned to ensure that they have also considered information that may be more recent than this document.

All standards, technical information reports, consensus reports and other types of technical documents developed by AAMI are *voluntary*, and their application is solely within the discretion and professional judgment of the user of the document. Occasionally, voluntary technical documents are adopted by government regulatory agencies or procurement authorities, in which case the adopting agency is responsible for enforcement of its rules and regulations.

Comments on this document are invited and should be sent to AAMI, Attn: Standards Department, 901 N. Glebe Rd, Suite 300, Arlington, VA 22203.

Published by

AAMI
901 N. Glebe Rd., Suite 300
Arlington, VA 22203
www.aami.org

© 2020 by the Association for the Advancement of Medical Instrumentation

All Rights Reserved

Publication, reproduction, photocopying, storage, or transmission, electronically or otherwise, of all or any part of this document without the prior written permission of the Association for the Advancement of Medical Instrumentation is strictly prohibited by law. It is illegal under federal law (17 U.S.C. § 101, *et seq.*) to make copies of all or any part of this document (whether internally or externally) without the prior written permission of the Association for the Advancement of Medical Instrumentation. Violators risk legal action, including civil and criminal penalties, and damages of \$100,000 per offense. For permission regarding the use of all or any part of this document, visit the [Copyright Clearance Center](#).

Printed in the United States of America

ISBN 978-1-57020-762-4

Contents

Page

Task Group representation	iv
Acknowledgments	v
Purpose	1
1 Working Pressure	1
2 Accessories	1
3 Resistance to flow (pressure drop)	1
4 Breathing during single fault condition	2
5 CO ₂ Rebreathing	2
6 Fresh Gas Port	2
7 Reuse hazards	2
8 Biocompatibility	2
9 Risk Management Process	3
10 Acoustic noise	3
11 Oxygen enriched environment	3
12 Volume	4

Task Group representation

Association for the Advancement of Medical Instrumentation

COVID-19 Response Team Members

This AAMI Consensus Report (CR) was developed by a task group under the auspices of the AAMI COVID-19 Response Team.

The **AAMI COVID-19 Response Team** had the following members:

Cochairs: Jennifer Danieleley
David Feinstein
Julian Goldman
Sandy Weininger

Members: Simona Bancos, FDA/CDRH
Andrew Bath, ResMed Inc.
Brandon Blakely, FDA/CDRH
Brad Bonnette, ECRI Institute
Caitlin Brady, Intertek
David Busch, UT Southwestern Medical Center
Anthony Ciccarello, Philips
Steven Dain, University of Western Ontario
Rakhi Dalal, FDA/CDRH
Jennifer Danieleley, FDA/CDRH
Andy Doering, Medtronic
Simon Dunham, Weill Cornell Medicine
David Feinstein, American Society of Anesthesiologists (ASA)
Bruce Friedman, GE Healthcare
Hamed Ghods, FDA/CDRH
Julian Goldman, Partners HealthCare System
Ralf Heesch, Draeger Medical Systems Inc.
Heidi Horn, Nuvolo Technologies
Fernando Isaza, Philips
Michael Jaffe, Cardiorespiratory Consulting LLC
Gardner Kimm, Medtronic Inc Campus
Robert Kopotic, Edwards Lifesciences
Hubertus Lasthaus, VitalAire Germany
Ed Madsen, Avanos Medical
Phoebe Mainland, Alfred Health
Madeleine Manousaridis, Standards Australia
Benoit Marchal, Air Liquide
Thomas Marmet, GE Healthcare
Debra Milamed, Harvard University
Cyndy Miller, Medtronic Inc Campus
Bryant Moeller, ResMed Inc.
Curtis Morgan, 3M Health Care
Akito Ohmura, Teikyo University-Mizonokuchi Hospital
David Osborn, Philips
John Stark, 3M Health Care
Robert Steurer, Steurer Consulting Group
Dongbo Wang, FDA/CDRH
Sandy Weininger, FDA/CDRH
Ayub Yancheshmeh, CSA Group

NOTE—Participation by federal agency representatives in the development of this document does not constitute endorsement by the federal government or any of its agencies.

Acknowledgments

AAMI gratefully acknowledges the writing team members, Prepared by Brad Bonnette, Anthony Ciccarello, Rakhi Dalal, Julian Goldman, Barry Hunt, Bob Kopotic, Ken LeDez, Cyndy Miller, Dave Osborn and Sandy Weinger for their outstanding and expeditious work in preparing these drafts for committee review and approval.

End user disclosures for emergency use Ventilatory Assistance Helmet (VAH)

Purpose

This document identifies safety related disclosures to be provided to end users of Emergency Use VAH. These details are based on the hazards identified in IEC 60601-1¹ and ISO 17510².

1 Working Pressure

Purpose: to ensure compatibility of the VAH interface with the patient and source of ventilatory assist.

Disclosures:

Indicate the rated:

- MAXIMUM WORKING PRESSURE
- minimum pressure

2 Accessories

Purpose: to ensure the safe use of the VAH with compatible accessories.

Disclosures:

List of recommended accessories and their replacement intervals e.g., tubing, filters, valves, monitoring systems.

List of recommended fresh gas sources e.g. ventilators, ventilatory assist equipment, gas mixers, flow meters.

3 Resistance to flow (pressure drop)

Purpose: to ensure the patient receives the required therapeutic pressure and to limit the inspiratory and expiratory resistance to an acceptable level.

Disclosures:

Inspiratory resistance: The resistance to inspiratory flow derived from pressure drop between the patient connection port and the patient measured at 50L/min and 100L/min.

¹ Medical electrical equipment – Part 1: General requirements for basic safety and essential performance

² Medical devices — Sleep apnoea breathing therapy — Masks and application accessories

27 Expiratory resistance: The resistance to expiratory flow derived from pressure drop between the interior
28 of the VAH and ambient, measured at 50L/min and 100L/min.

29 **4 Breathing during single fault condition**

30 Purpose: to limit breathing resistance and to prevent excessive rebreathing when there is insufficient
31 fresh gas flow from the ventilatory assist equipment during a single fault condition.

32 Disclosures:

33 If an anti-asphyxia valve is provided, the open-to-atmosphere and closed-to-atmosphere pressures
34 shall be disclosed.

35 If an anti-asphyxia valve is not provided in the VAH, manufacturers shall disclose the means by which
36 the patient shall access fresh gas in the case of a SINGLE FAULT CONDITION.

37 Manufacturers shall disclose the necessity of continual monitoring of the patient by the operator and/or
38 by monitoring equipment capable of creating alarm conditions in the case of faults.

39 **5 CO₂ Rebreathing**

40 Purpose: to reduce the risk of excessive inspired carbon dioxide

41 Disclosures:

42 Disclose the minimum flow required to prevent unacceptable CO₂ rebreathing.

43 Describe the means implemented to minimize the risk of rebreathing exhaled CO₂. The means can be
44 included in the VAH or the equipment providing gas delivery or ventilation.

45 **6 Fresh Gas Port**

46 Purpose: since the source of fresh gas is not included in the VAH, identify the pressure or supplemental
47 oxygen delivery interface.

48 Disclosures:

49 Disclose the means of interfacing with the fresh gas delivery system or ventilatory assist device.

50 **7 Reuse hazards**

51 Purpose: to reduce the risk of cross-contamination.

52 Disclosures:

53 Describe the cleaning and disinfection procedures needed between uses and between patients for both
54 the VAH and accessories.

55 Description of location and specifications of required VAH viral filters and replacement intervals.

56 **8 Biocompatibility**

57 Purpose: to reduce the risk of biological reaction to foreign substances.

58 Disclosures:

59 For the gas pathway, indicate if any biocompatibility evaluations were performed per ISO 18562
60 (series)³.

61 For parts intended to touch the patient, indicate if any biocompatibility evaluations were performed per
62 ISO 10993 (series)⁴.

63 **9 Risk Management Process**

64 Purpose: to ensure risks were comprehensively identified and adequately managed.

65 Disclosures:

66 Indicate whether the VAH design has been developed using a risk management process (e.g., ISO
67 14971⁵).

68 **10 Acoustic noise**

69 Purpose: to ensure acoustic noise inside the VAH is at an acceptable patient level.

70 Disclosures:

71 Disclose if hearing protection is necessary and provided by the VAH manufacturer. If not provided by
72 the VAH manufacturer provide the requirements for such hearing protection.

73 If measured, disclose in dBA the acoustic noise level measured at the minimum required fresh gas
74 flowrate

75 **11 Oxygen enriched environment**

76 Purpose: to reduce the risk of thermal injury resulting from ignition of the VAH or its accessories when
77 the VAH is used with supplemental oxygen therapy.

78 Disclosures:

79 Indicate that electronic devices used inside or in the vicinity of the VAH shall be suitable for use in an
80 oxygen enriched environment > 25 % O₂. Examples of electronic devices are microphones,
81 headphones, cell phones, and electro-medical devices.

82 Indicate that the use of lotions, salves, dressing, makeup, or lubricants (e.g., grease for O-rings and
83 fittings on device) in an oxygen enriched environment requires special consideration.

84 If alcohol or flammable cleaning or disinfection agents are used, ensure that they have completely
85 evaporated prior to use.

86 Examples:

87 a warning statement to the effect that "WARNING: Use only water-based lotions, salves or
88 dressings that are oxygen-compatible before and during oxygen therapy. Never use these
89 products to avoid the risk of fire and burns".

³ Biocompatibility evaluation of breathing gas pathways in healthcare applications.

⁴ Biological evaluation of medical devices

⁵ Medical devices - Application of risk management to medical devices

90 a warning statement to the effect that "WARNING: Do not use lubricant for any fittings,
91 connections, tubing, or other accessories unless certified for use in an oxygen enriched
92 atmosphere to avoid the risk of fire and burns."

93 **12 Volume**

94 Purpose: Provide health care providers with information to better understand the device.

95 Disclosures:

- 96 • Approximate volume of gas with the helmet during NORMAL USE